Jack Chen
Scientific Director - Translational Oncology, Precision Medicine Abbvie
Seminars
Tuesday 13th October 2026
Presentation Preview: Employing Biomarker-Based ADC Translational Studies to Identify Patients Most Sensitive to ADC Performance
- Prioritizing biomarker and patient selection approaches to reflect a maturing ADC clinical development pipeline
- Highlighting biomarker development to identify patients with the most sensitive ADC response
- Utilizing reverse translation approaches to understand mechanisms behind clinical success to apply to ongoing ADC translational studies
